Table 1 Secondary adverse events and contraindications of treatments in HAE-C1-INH
Drug | Secondary Adverse Events | Contraindications |
|---|---|---|
Attenuated androgens | Virilization, headache, depression, weight gain, menstrual irregularities, sleeplessness, agitation, mood changes, arterial hypertension, dyslipemia, decreased libido and hepatotoxiciy [14–17]. | Pregnancy, lactation, childhood, breast cancer, prostate carcinoma, nephrotic syndrome, significant alteration of hepatic function [7]. |
Antifibrinolytics | Nausea, vomiting, headache, diarrhea, orthostatic regulation disturbances, myositis, muscle necrosis, increase in the risk of thrombosis [1]. | History of thrombosis or thromboembolism [7]. |
Fresh frozen plasma | Transmission of infectious diseases, potential aggravation of edema symptoms due to substrate supply that may lead to an increase of bradykinin, alloimmunization, anaphylactic or allergic reactions, excessive intravascular volume with risk of hypervolemia and heart failure [7]. | |
pdhC1INH | Potential transmission of infectious and/or pathogenic viruses [18], infection at injection site and thrombosis associated with indwelling catheters used for the administration of long-term prophylaxis with pdhC1inh concentrate [12]. | |
Icatibant acetate | Minor local adverse effects (self-limited erythema, pruritus and pain in injection area) [19, 20]. | Active ischemic heart diseaseIctus in previous 2 weeks [20]. |
Ecallantide | Anaphylactic and other acute allergic reactions [21] | |
Recombinant human C1INH | Allergic reaction [22]. | Rabbit allergy [7]. |